Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Guardant Health files suit against Tempus AI
Biotech
Guardant Health files suit against Tempus AI
Biotech takes legal action against Tempus AI, alleging patent infringement in Tempus's liquid biopsy products | Complaint accuses Tempus of unauthorised use of Guardant's tech crucial for cancer diagnostics.   13 June 2024
Greenberg Traurig adds medtech expert as shareholder
Careers
Greenberg Traurig adds medtech expert as shareholder
Latest addition to the firm brings medtech expertise and experience assisting digital health companies using AI and machine learning | Move comes at a time when “health care companies are thinking more like technology companies”.   6 June 2024
Biopharma sues USPTO over rejected shock therapy patent
Biotech
Biopharma sues USPTO over rejected shock therapy patent
Complaint sought judicial validation of the company's patent claims for a distributive shock treatment | Disputes the PTAB's decision deeming the invention obvious.   6 June 2024
article
Looking back at the UPC’s ‘successful’ first year
Court seen as “exceeding expectations” | Experts urge caution, emphasising that confident and reliable court judgments are needed | High-stakes patent litigation, especially in pharmaceuticals, remains predominantly within national courts.   4 June 2024
Europe
WIPO adopts first-of-its-kind treaty on genetic resources and traditional knowledge
WIPO member states approve treaty addressing IP issues related to genetic resources and traditional knowledge | Agreement marks new era for IP rights and Indigenous Peoples, introducing international legal requirements for patent applicants.   28 May 2024
Biotech
Moderna prevails in COVID-19 vaccine row at EPO
Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations.   21 May 2024
Europe
Moderna’s COVID-19 pledge dilemma
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.   16 May 2024
Americas
LSPN Spring: ‘Outside counsel teams must match partner's strength’
An LSPN panel discusses the challenges and strategies for effective collaboration between in-house counsel and outside legal teams, stressing the importance of communication, strategic planning, and clear expectations.   14 May 2024
Americas
LSPN Spring: Section 101 uncertainty ‘impacts US prosecution’
As Congress considers the Patent Eligibility Restoration Act of 2023, experts from NeoGenomics, Biogen, and Choate Hall & Stewart at LSPN Spring weigh in on its potential effect and the need for further clarification to improve patent eligibility standards.   13 May 2024
Europe
LSPN Spring: Preliminary injunctions ‘a focal point’ in UPC decisions
A significant uptake in unitary patents show court is here “in a big way” | Speakers shed light on the UPC's approach to preliminary injunctions and evidence gathering at LSPN Spring in Boston.   9 May 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.